Please ensure Javascript is enabled for purposes of website accessibility

Why GW Pharmaceuticals Shares Tumbled 25% in January

By Todd Campbell – Feb 2, 2016 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Worry over financial controls is weighing down shares in the once-promising marijuana drugmaker.

Image source: GW Pharmaceuticals, plc.

What: Following reports that the company's financials may lack adequate accounting controls, shares in GW Pharmaceuticals, plc (GWPH) fell 25.3% in January, according to S&P Capital IQ.

So what: Early last month, the company disclosed that it has material weaknesses in its accounting practices related to clinical trial costs and milestones.

That's concerning given that there's tremendous trial activity occurring at the company.

GW Pharmaceuticals is one of the most committed drugmakers to the study of marijuana-derived medicine and its trials have included research into marijuana's use in cancer pain, diabetes, schizophrenia, and epilepsy.

In December, the company reported that its R&D costs were $25.5 million in its fiscal fourth quarter, up 107% from last year.

Now what: It's never encouraging to learn that management may not have as good a handle on the financials as thought and until it can put this issue behind it, it's likely that investors will remain cautious on this stock -- something that may not be a bad thing.

After all, GW Pharmaceuticals recent track record for clinical success is a bit more miss than hit. Last year, three separate cancer pain trials evaluating a THC-based medicine failed to beat placebo and a schizophrenia study led to more questions than answers. As a result, there's a lot of pressure on its ongoing epilepsy studies to pan out.

Absent a definitive clinical win in epilepsy and a restoration of confidence in the company's finances, the sidelines may be the best place for investors on this one. 


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.